MAAT INDEX

CLAIM #48454 · Pfizer Inc (PFE) · 2024Q3 earnings call · Oct 29, 2024 · due Dec 31, 2024

Regarding 2025, it's really topical because we're in the middle, as you can imagine, building our 2025 financial plan here across all of our business lines. It is our expectation that we will provide guidance for 2025, most likely by the end of this year.

David Denton · CFO

PENDING
graded after results covering Dec 31, 2024 are reported

In context

cluding Starboard and consider any good ideas that create long-term shareholder value. But I don’t think that the statement something needs to change is really pragmatic because it’s coming 15 months late. Operator: We'll take our next question from Louise Chen with Cantor. Louise Chen: So I just had two here. First one, I wanted to ask you is how we should think about the big pushes and pulls for sales and EPS in 2025? And when you might give guidance? Could it be as early as this year? And then second one, just on Seagen, just wondering how the integration is coming along and if you have any updates to some of the metrics that you gave like sales in 2030 and what have you for the Seagen deal? Albert Bourla: Okay. Dave, let's start with the first question. Dave Denton: Yes. So thank you. Regarding 2025, it's really topical because we're in the middle, as you can imagine, building our 2025 financial plan here across all of our business lines at -- to your point, there's going to be a lot of pushes and pulls as we think about growth into next year on both our core business as well as our COVID business. It is our expectation that we will provide guidance for 2025, most likely by the end of this year. So stay tuned, more to come. We will lay out all the pushes and pulls when we give guidance for 2025, so you can get a very clear understanding of our business and the opportunities to enhance shareholder value longer term. Albert Bourla: Chris, can you give us an update on the Seagen integration, both speak a little bit about the commercial, but also focus on the research, which is a significant value? Chris Boshoff: Thank you very much for the question. Overall, we're very pleased with the integration to date. We've retained the vast majority of colleagues at legacy Seagen, and we now have over 1,500 colleagues working in our

Verify independently

SEC filings for PFE · Claim quote is verbatim from the 2024Q3 earnings call.